In the Claims:

Please amend claims 1-6 and 8 as follows. Please add new claims 10-17.

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents selected from C_{1-6} alkyl, halosubstitutedC_{1-6} alkyl, C_{1-6} alkoxy, a hydroxy group, a cyano group, halo, a C_{1-6}alkylsulfonyl group, -$CONH_2$, -$NHCOCH_3$, -COOH halosubstitutedC_{1-6} alkoxy, $SO_2NR^{8a}R^{8b}$ and C_{1-6} alkynyl;

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, ~~or~~ and halosubstitutedC_{1-6} alkyl;

R^2 is $(CH_2)_mR^3$ where m is 0 or 1;

or R^1 and R^2 together with N to which they are attached form ~~an optionally substituted~~ 4- to 8- membered non-aromatic heterocyclyl ring optionally substituted with 1, 2 or 3 substituents selected from: C_{1-6} alkyl, C_{1-6} alkoxy, a hydroxy group, a cyano group, halo, a sulfonyl group, methylsulfonyl, NR^{8a} R^{8b}, CH_2phenyl, $NHCOCH_3$, (=O), $CONHCH_3$ or $NHSO_2CH_3$;

R^3 is a 4- to 8- membered non-aromatic heterocyclyl group, a C_{3-8} cycloalkyl group, a straight or branched C_{1-10} alkyl, a C_{2-10}alkenyl, a C_{3-8}cycloalkenyl, a C_{2-10}alkynyl, or a C_{3-8}cycloalkynyl any of which can be unsubstituted ~~unsubtituted~~ or substituted with C_{1-6} alkyl, C_{1-6} alkoxy, a hydroxy group, a cyano group, halo, a sulfonyl group, methylsulfonyl, NR^{8a} R^{8b}, CH_2phenyl, $NHCOCH_3$, (=O), $CONHCH_3$ or $NHSO_2CH_3$ or R^3 can be ~~or~~ R^5;

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstitutedC_{1-6} alkyl, $COCH_3$, ~~or~~ and SO_2Me;

R^5 is



wherein p is 0, 1 or 2, and X is CH_2, O, or S;

R^6 is a substituted or unsubstituted (C_{1-6})alkyl or chloro and R^{10} is hydrogen or R^{10} is a substituted or unsubstituted (C_{1-6})alkyl or chloro and R^6 is hydrogen wherein said substituted (C_{1-6})alkyl group is substituted with 1, 2 or 3 substitutents selected from hydroxy, C_{1-6}alkyoxy, cyano, halo, $NR^{8a}R^{8b}$, $CONR^{8a}R^{8b}$, $SO_2NR^{8a}R^{8b}$, $NR^{8a}COR^{8b}$ and $NR^{8a}SO_2R^{8b}$;

R^7 is OH, C_{1-6}alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$ or $SOqR^9$;

R^{8a} is H or C_{1-6}alkyl;

R^{8b} is H or C_{1-6}alkyl;

R^9 is C_{1-6}alkyl;

q is 0, 1 or 2;

or a pharmaceutically acceptable derivative thereof.

2. (Currently Amended) A compound ~~as claimed in claim 1~~ of formula (Ia):



(Ia)

R^1 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, ~~or~~ and halosubstitutedC_{1-6} alkyl;

R^2 is $(CH_2)_mR^3$ where m is 0 or 1;

or R^1 and R^2 together with N to which they are attached form a non-aromatic heterocyclyl ring selected from azetidinyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, tetrahydropyridinyl, azapine, oxapine, azacyclooctanyl, azaoxacyclooctanyl and azathiacyclooctanyl, any of which can be unsubstituted or substituted with 1, 2 or 3 substituents selected from; C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, methylsulfonyl, $NR^{8a}R^{8b}$, CH_2phenyl, $NHCOCH_3$, (=O), $CONHCH_3$ and $NHSO_2CH_3$;

R^3 is 2- or 3- azetidinyl, oxetanyl, thioxetanyl, thioxetanyl-s-oxide, thioxetanyl-s,s-dioxide, dioxalanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrahydrothiophenyl-s,s-dioxide, morpholinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, thiomorpholinyl, thiomorpholinyl-s,s-dioxide, tetrahydropyridinyl, dioxanyl, tetrahydro-thiopyran 1,1 dioxide, azapine, oxapine, azacyclooctanyl, azaoxacyclooctanyl, azathiacyclooctanyl, oxacylcooctanyl, thiacyclooctanyl, a C_{3-8} cycloalkyl group, a straight or branched C_{1-10} alkyl, a C_{2-10}alkenyl, a C_{3-8}cycloalkenyl, a C_{2-10}alkynyl, or a C_{3-8}cycloalkynyl or R^5; any of which can be unsubstituted or substituted with 1, 2 or 3 substituents selected from C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, sulfonyl, methylsulfonyl, $NR^{8a}R^{8b}$, CH_2phenyl, $NHCOCH_3$, (=O), $CONHCH_3$ and $NHSO_2CH_3$;

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, or halosubstitutedC_{1-6} alkyl, $COCH_3$, ~~or~~ and SO_2Me;

R^5 is



wherein p is 0, 1 or 2, and X is CH_2, O or S;

R^6 is a substituted or unsubstituted (C_{1-6})alkyl or chloro and R^{10} is hydrogen or R^{10} is a substituted or unsubstituted (C_{1-6})alkyl or chloro and R^6 is hydrogen wherein said substituted (C_{1-6})alkyl group is substituted with 1, 2 or 3 substitutents selected from hydroxy, C_{1-6}alkyoxy, cyano, halo, $NR^{8a}R^{8b}$, $CONR^{8a}R^{8b}$, $SO_2NR^{8a}R^{8b}$, $NR^{8a}COR^{8b}$ and $NR^{8a}SO_2R^{8b}$;

R^7 is OH, C_{1-6}alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$ or $SOqR^9$;

R^{8a} is H or C_{1-6}alkyl;

R^{8b} is H or C_{1-6}alkyl;

R^9 is C_{1-6}alkyl;

R^{11} is C_{1-6} alkyl, halosubstitutedC_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, cyano, halo, C_{1-6}alkylsulfonyl group, $-CONH_2$, $-NHCOCH_3$, -COOH, halosubstituted C_{1-6} alkoxy $SO_2NR^{8a}R^{8b}$ or C_{1-6} alkynyl;

q is 0, 1 or 2;

d is 0,1, 2, or 3;

or a pharmaceutically acceptable derivative thereof.

3. (Currently Amended) A compound as claimed in claim 1 ~~or 2~~ wherein R^1 is hydrogen.

4. (Currently Amended) A compound as claimed in ~~any preceding~~ claim 1 wherein R^4 is C_{1-6} alkyl or hydrogen.

5. (Currently Amended) A compound as claimed in ~~any preceding~~ claim 1 wherein R^6 is *t*-butyl, isopropyl or CF_3.

6. (Currently Amended) A pharmaceutical composition comprising a compound as claimed ~~any preceding~~ in claim 1 ~~or a pharmaceutically acceptable derivative thereof~~.

7. (Original) A pharmaceutical composition as claimed in claim 6 further comprising a pharmaceutical carrier or diluent thereof.

8. (Currently Amended) A method of treating a ~~human or animal subject~~ mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said mammal ~~subject~~ a therapeutically effective amount of a compound ~~of formula (I)~~ as claimed in claim 1 ~~any one of claims 1 to 5 or a pharmaceutically acceptable derivative thereof~~.

9. (Original) A method of treatment as claimed in claim 8 wherein the condition is an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis.

10. (New) The method as claimed in claim 9, wherein said pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine.

11. (New) The method as claimed in claim 8, wherein said mammal is a human.

12. (New) A compound selected from

6-(3-Chloro-phenyl-amino)-4-isopropyl-N-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

6-(3-Bromo-phenyl-amino)-4-isopropyl-N-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

6-(2,4-Dichloro-phenylamino)-4-isopropyl-N-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

4-Isopropyl-N-(tetrahydro-pyran-4-ylmethyl)-6-(3-trifluoromethoxy-phenylamino)-nicotinamide;

4-*tert*-Butyl-6-(2,4-di-chloro-phenylamino)-N-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

6-(3-Chloro-4-cyano-phenylamino)-4-isopropyl-N-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

6-(2-Fluoro-3-trifluoromethyl-phenylamino)-4-isopropyl-N-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

6-(4-Bromo-2-chloro-phenylamino)-4-isopropyl-N-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

6-(3,4-Dichloro-phenylamino)-4-isopropyl-N-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

6-(2-Bromo-4-trifluoromethoxy-phenylamino)-4-isopropyl-*N*-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

6-(3,5-Difluoro-phenylamino)-4-isopropyl-*N*-(tetrahydro-pyran-4-ylmethyl)-nicotinamide;

6-(2,4-Dichloro-phenylamino)-N-(tetrahydro-pyran-4-ylmethyl)-4-trifluoromethyl-nicotinamide;

and pharmaceutically acceptable derivatives thereof.

13. (New) A pharmaceutical composition comprising a compound as claimed in claim 12.

14. (New) A method of treating a mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said mammal a therapeutically effective amount of a compound as claimed in claim 12.

15. (New) A method of treatment as claimed in claim 14 wherein the condition is an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis.

16. (New) The method as claimed in claim 15, wherein said pain is selected from inflammatory pain, viseral pain, cancer pain, neuropathic pain, lower back pain, muscular sceletal, post operative pain, acute pain and migraine.

17. (New) The method as claimed in claim 14, wherein said mammal is a human.